Quoin Pharmaceuticals Ltd
quoinpharma.comWhat Do They Do?
Develops topical drug candidates for rare and orphan diseases, including treatments for genetic skin disorders and topical formulations for other rare conditions.
10-K for FY2025, filed Mar 26, 2026We are a late-stage clinical specialty pharmaceutical company focused on the development and commercialization of therapeutic products that…View ↗
QRX003 is a topical lotion being developed for the treatment of a number of rare genetic skin diseases. Our most advanced program is for…View ↗
On June 10, 2024 we signed a research agreement with UCC. The scope of the agreement encompasses the development of novel topical…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2021, filed Apr 14, 2022
Who Are Their Customers?
The company plans to use its own sales infrastructure in the U.S., Europe and Japan, and distribution partners in other territories to commercialize QRX003 if approved.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$5.4MView ↗
- ▲ +45% (Loss)
- vs −$3.7M in Q2 FY2025
Topical rapamycin added
The latest report adds a research program for topical rapamycin formulations for rare and orphan diseases; the older report instead describes university research agreements for treatments aimed at Netherton syndrome and scleroderma.
10-K for FY2022, filed Mar 15, 2023 10-K for FY2025, filed Mar 26, 2026In November 2021, we entered into the Research Agreement with QUT, pursuant to which we have an option to in-license the QRX007 product.…View ↗
Who Do They Compete With?
Competes with LifeMax Laboratories, Sixera Pharmaceuticals, ResVita Bio, BioCryst, and Azitra
10-K for FY2025, filed Mar 26, 2026The clinical biotechnology industry is a competitive industry characterized by technological innovation and growth. Our competitors include…View ↗
Loading...
